1.6500
-0.0300
(-1.79%)
At close: April 15 at 4:00:00 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 8.37M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| HERSHBERG ROBERT M Chief Executive Officer | Sale at price 1.76 - 1.89 per share. | Direct | 48,661 | Feb 11, 2025 |
| MALTBIE SHANE Chief Financial Officer | Sale at price 1.76 - 1.89 per share. | Direct | 15,117 | Feb 11, 2025 |
| KOHLI ADITYA PH.D. Director | Sale at price 14.21 - 15.45 per share. | Direct | 266,291 | May 22, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 14.01 - 14.15 per share. | Direct | 96,770 | May 3, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 14.44 - 14.93 per share. | Direct | 264,467 | Apr 5, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.50 per share. | Indirect | 128,325 | Apr 4, 2024 |
| FRAZIER LIFE SCIENCES X, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.50 per share. | Indirect | 128,325 | Apr 4, 2024 |
| MCLOUGHLIN SEAN Chief Operating Officer | Purchase at price 16.98 per share. | Direct | 21,225 | Mar 28, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 17.42 - 17.66 per share. | Direct | 315,008 | Mar 20, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 18.37 - 18.95 per share. | Direct | 335,872 | Mar 8, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 14.88 - 15.05 per share. | Direct | 269,078 | Feb 22, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 15.32 per share. | Direct | 91,921 | Feb 12, 2024 |
| HERSHBERG ROBERT M Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 8, 2024 |
| HERSHBERG ROBERT M Chief Executive Officer | Sale at price 14.93 per share. | Direct | 173,161 | Feb 8, 2024 |
| MALTBIE SHANE Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 8, 2024 |
| MALTBIE SHANE Chief Financial Officer | Sale at price 14.93 per share. | Direct | 53,395 | Feb 8, 2024 |
| KOHLI ADITYA PH.D. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 8, 2024 |
| KOHLI ADITYA PH.D. Director | Sale at price 14.93 per share. | Direct | 132,383 | Feb 8, 2024 |
| BORKOWSKI ASTRID Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 8, 2024 |
| BORKOWSKI ASTRID Officer | Sale at price 14.93 per share. | Direct | 58,726 | Feb 8, 2024 |
| BORKOWSKI ASTRID Officer | Sale at price 15.50 per share. | Direct | 155,000 | Dec 15, 2023 |
| BORKOWSKI ASTRID Officer | Sale at price 14.20 - 14.50 per share. | Direct | 287,000 | Dec 4, 2023 |
| BORKOWSKI ASTRID Officer | Sale at price 14.00 per share. | Direct | 140,000 | Nov 17, 2023 |
| BORKOWSKI ASTRID Officer | Sale at price 13.00 per share. | Direct | 65,000 | Nov 8, 2023 |
| HERSHBERG ROBERT M Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2023 |
| MALTBIE SHANE Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2023 |
| KOHLI ADITYA PH.D. Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2023 |
| BORKOWSKI ASTRID Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2023 |
| TAKEDA PHARMACEUTICAL CO., LTD. Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 0.00 per share. | Indirect | 588 | Nov 30, 2022 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | Indirect | 30,000,002 | May 3, 2022 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 13.60 per share. | Indirect | 37,212,782 | May 3, 2022 |
| FRAZIER LIFE SCIENCES X, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | Indirect | 30,000,002 | May 3, 2022 |
| FRAZIER LIFE SCIENCES X, L.P. Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 13.60 per share. | Indirect | 37,212,782 | May 3, 2022 |
Related Tickers
EPIX ESSA Pharma Inc.
1.6300
-1.21%
TBPH Theravance Biopharma, Inc.
8.63
-1.15%
ANTX AN2 Therapeutics, Inc.
1.2600
-3.82%
IPSC Century Therapeutics, Inc.
0.5010
+0.36%
ASMB Assembly Biosciences, Inc.
9.81
-3.82%
RPTX Repare Therapeutics Inc.
1.1000
+18.51%
GLTO Galecto, Inc.
2.5700
+3.21%
SPRO Spero Therapeutics, Inc.
0.7444
+6.19%
CLRB Cellectar Biosciences, Inc.
0.2936
-0.31%
TIL Instil Bio, Inc.
16.48
-1.90%